Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2025 | $36.00 | Buy | Stifel |
| 3/25/2025 | $23.00 | Buy | Jefferies |
| 2/28/2025 | $48.00 | Overweight | Piper Sandler |
| 2/21/2025 | $18.00 | Outperform | Wedbush |
| 12/19/2024 | $40.00 | Buy | BTIG Research |
| 10/24/2024 | Neutral | H.C. Wainwright | |
| 4/16/2024 | $35.00 | Perform → Outperform | Oppenheimer |
| 3/3/2022 | $5.00 → $0.75 | Buy → Hold | Jefferies |
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New YorkFireside ChatJune 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New YorkPanelist: "Dermatology: AA, HS, PSO"June 25, 2025, at 10am ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available f
Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025. "We have made considerable progress in our Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with site activations, screenings
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
S-8 - Avalo Therapeutics, Inc. (0001534120) (Filer)
SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00
Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00
Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00